Long-term results of the Polish Adult Leukemia Group PALG-CLL2 phase III randomized study comparing cladribine-based combinations in chronic lymphocytic leukemia. Issue 3 (March 2014)

• Record Type: Journal Article
• Authors: Robak, Tadeusz; Blonski, Jerzy Z.; Gora-Tybor, Joanna; Calbecka, Malgorzata; Dwilewicz-Trojaczek, Jadwiga; Boguradzki, Piotr; Dmoszynska, Anna; Kowal, Malgorzata; Kloczko, Janusz; Piszcz, Jaroslaw; Stella-Holowiecka, Beata; Sulek, Kazimierz; Kuliczkowski, Kazimierz; Potoczek, Stanislaw; Warzocha, Krzysztof; Lech-Maranda, Ewa; Skotnicki, Aleksander B.; Piotrowska, Magdalena; Moskwa, Andrzej; Zawilska, Krystyna; Jamroziak, Krzysztof
• Is Part Of: Leukemia & lymphoma. Volume 55:Issue 3(2014:Mar.)
• Page Start: 606
• Page End: 610
• Publication Date: 2014-03
• Subjects: Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.3109/10428194.2013.809073
• Languages: English
• ISSNs: 1042-8194

Abstract

<abstract> <title>Abstract</title> <p>Long-term outcomes following newer therapies for chronic lymphocytic leukemia (CLL) have rarely been reported. This article presents the results of the final analysis of the Polish Adult Leukemia Group PALG-CLL2 study performed 10 years from final patient enrollment. With the extended follow-up time, it was found that cladribine (2-CdA)-based combinations CMC (2-CdA, cyclophosphamide, mitoxantrone) and CC (2-CdA, cyclophosphamide) administered as first-line treatment of progressive CLL resulted in significantly longer progression-free survival, but similar overall survival compared to 2-CdA monotherapy. Furthermore, the risk of potentially fatal late adverse events including infections, autoimmune complications and, particularly, secondary neoplasms was comparable among patients treated with CMC, CC or 2-CdA. The results of our analysis support the importance of long-term outcome monitoring of randomized trials in CLL.</p> </abstract>